The new office will incorporate the company’s commercialization team handling, while retaining its corporate headquarters, with clinical, manufacturing, regulatory and administration functions, remains in Dublin, Ohio, US.
Navidea president and CEO Mark Pykett said the expansion into Boston area will enhance their access to industry partners, key business and technical leaders, and major academic medical centers.
"This is an important commercial and business development expansion for us, complementing our established Ohio-based corporate office, as we prepare for the anticipated marketing approval in the US for Lymphoseek, international activities for the product, and the growth of our radiopharmaceutical pipeline," Pykett added.
Navidea Biopharmaceuticals is focused on the development and commercialization of precision diagnostics and radiopharmaceutical agents including Lymphoseek, AZD4694 and RIGScan.
The company expects the launch of Lymphoseek later this year.